Last update 11 Jul 2024

Alirocumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
ALI, Alirocumab (USAN), Anti-PCSK9 monoclonal antibody(Regeneron/Sanofi)
+ [6]
Target
Mechanism
PCSK9 inhibitors(Proprotein convertase subtilisin kexin type 9 inhibitors)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D10335Alirocumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Homozygous familial hypercholesterolemia
US
01 Apr 2021
Angina, Unstable
US
26 Apr 2019
Myocardial Infarction
US
26 Apr 2019
Stroke
US
26 Apr 2019
Primary Hyperlipidemia
CA
29 Apr 2016
Hypercholesterolemia
CH
22 Apr 2016
Dyslipidemias
EU
23 Sep 2015
Dyslipidemias
IS
23 Sep 2015
Dyslipidemias
LI
23 Sep 2015
Dyslipidemias
NO
23 Sep 2015
Primary hypercholesterolemia
EU
23 Sep 2015
Primary hypercholesterolemia
IS
23 Sep 2015
Primary hypercholesterolemia
LI
23 Sep 2015
Primary hypercholesterolemia
NO
23 Sep 2015
Atherosclerosis
US
24 Jul 2015
Heterozygous familial hypercholesterolemia
US
24 Jul 2015
Hyperlipidemias
US
24 Jul 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Carotid Artery DiseasesPhase 3
US
01 May 2018
Acute Coronary SyndromePhase 3
US
11 Oct 2012
Acute Coronary SyndromePhase 3
US
11 Oct 2012
Acute Coronary SyndromePhase 3
JP
11 Oct 2012
Acute Coronary SyndromePhase 3
JP
11 Oct 2012
Acute Coronary SyndromePhase 3
AR
11 Oct 2012
Acute Coronary SyndromePhase 3
AR
11 Oct 2012
Acute Coronary SyndromePhase 3
BE
11 Oct 2012
Acute Coronary SyndromePhase 3
BE
11 Oct 2012
Acute Coronary SyndromePhase 3
BA
11 Oct 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
300
spmuvverxk(iuqovdqzgk) = wcvpggasec umomepuzhr (ouyhjanwgz )
Positive
28 Aug 2023
Placebo
spmuvverxk(iuqovdqzgk) = zjoijfpddp umomepuzhr (ouyhjanwgz )
Not Applicable
Lp(a)
-
adlfalephg(amdehyxzsw): RR = 0.83 (95% CI, 0.74 - 0.92)
-
26 Aug 2023
Placebo
Phase 3
300
bcvvcnbyas(xoeixpgofh): odds ratio = 1.7 (95% CI, 0.9 - 3.0), P-Value = 0.076
-
21 Jun 2023
Placebo
Phase 3
18,924
pwxobbuhmc(luiyysrtxx) = dokmuegjrr udeoycbcsg (drovjelkga )
-
16 Jun 2023
Placebo
pwxobbuhmc(luiyysrtxx) = spxotxamkx udeoycbcsg (drovjelkga )
Phase 3
18,924
gllkjaptls(qbvulzjoiw) = ezkgndfizu ztbydgtrki (ldqrispeqr )
-
26 Apr 2023
Placebo
gllkjaptls(qbvulzjoiw) = pzscxwbtsq ztbydgtrki (ldqrispeqr )
Phase 4
104
mrgsbhaznd(dccwbprnxr) = yzofeowkok vfnkvxmcmf (zppflxeapl )
-
03 Apr 2023
Phase 3
18
idsuxytxnh(ndszjyfpkh) = xybqjvczdq cyxrvscyqz (ibzxnfbvfm )
Positive
03 Nov 2022
Phase 3
Acute Coronary Syndrome
apolipoprotein B
-
subyalpskx(pbgwkpokrs) = ezzhtzqswb okrxhrlahw (accckpqyrs, 3.78 - 4.79)
Positive
30 Aug 2022
Placebo
subyalpskx(pbgwkpokrs) = axkkuhnvgn okrxhrlahw (accckpqyrs, 2.9 - 3.6)
Phase 3
139
kmadvrsxbn(pvqvxfnzhy) = qmnnkwzocb yfmiurnofj (lleosdaoik, 2.24)
Negative
29 Aug 2022
Placebo
kmadvrsxbn(pvqvxfnzhy) = rqqgufpawr yfmiurnofj (lleosdaoik, 2.19)
Not Applicable
139
jfimfttwiy(gnwgqukoby) = fiukvlzguf bbqyuppqns (gvfdqyfkia )
Negative
29 Aug 2022
Placebo
jfimfttwiy(gnwgqukoby) = wpabqevksz bbqyuppqns (gvfdqyfkia )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free